Posts related to ‘Drug companies’

The Best Short-Selling Opportunities Of The Year (C)(GE)(F)(SBUX)(SIRI)

angrybearThere is still some conversation about the federal government restricting short-selling activity in certain stocks. The counterargument to these restrictions is that short selling plays an important role in the valuation of securities by efficiently allowing investors to bet that a stock will fall as readily as they can bet that it will rise. Short sellers have the reputation, whether deserved or not, for trying to manipulate information about public companies with the hope of driving their prices down. That may be true.

24/7 Wall St. has come up with a list of the best short-selling opportunities between now and the end of the year. The list was chosen based on: 1) trading volume, 2) the total short position in the stock over the first half of the year, 3) a history of the short position in these stocks rising or falling rapidly, and 4) stocks in companies that tend to move on news throughout the year and not just on earnings information. Read More »

Media Digest 7/1/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   California raced to approve a state budget its cutting deficit.

Reuters:   Ten more people may face charges in Madoff case.

Reuters:   Gannett (GCI) is laying off 1,000 more people.

Reuters:   China will delay a web filter for PCs sold in the country.

Reuters:   B of A’s (BAC) asset management unit got low bids.

Reuters:   Monster’s June job index fell.

Read More »

GE Taking Decisive Step Into Stem Cells (GE, GERN, STEM, ASTM)

GE LogoGeneral Electric Company (NYSE: GE) is taking a bold and controversial new step into the field of embryonic stem cell research.  The company has signed an exclusive license and alliance pact with Geron Corporation (NASDAQ: GERN) to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening.  As noted over at BioHealthInvestor.com, this may have implications for other stem cell stocks such as StemCells Inc. (NASDAQ: STEM), Aastrom Biosciences, Inc. (NASDAQ: ASTM) and others.
Read More »

Media Digest 8/30/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   Cybercrime is spreading fast on Facebook.

Reuters:   GM will seek to sell most of its assets to a new company.

Reuters:    Madoff got 150 years in prison.

Reuters:   AIG (AIG) shareholders will elect new directors.

Reuters:   GM is close to a deal to sell Opel.

Reuters:   A jury returned a $1.7 billion drug verdict against Abbot (ABT). Read More »

Media Digest 6/29/2009

newspaperReuters:   GM will accept product liability on cars it has built in the past.

Reuters:   Obama could consider a second stimulus if necessary.

Reuters:   Rising office availability in NYC is slowing.

Reuters:   VW says it has not issued an ultimatum to Porsche on a tie-up.

Reuters:   Tata launched Jaguar and Rover in India. Read More »

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early afternoon Thursday after Japan okayed one of the company’s human growth hormones, the first approval in Japan of a generic biotech drug.  With the recent talks of President Obama wanting generic biologics, the approval process in Japan is probably not an isolated event and should not be ignored for broader implications.
Read More »

Media Digest 6/24/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   The head of a Congressional watchdog committee is pushing for a consumer protection agency.

Reuters:   China defended its export policies against a WTO complaint.

Reuters:   Citigroup (C) intends to raise the base pay of key employees.

Reuters:   Apple’s (AAPL) Jobs has an excellent prognosis after recent surgery. Read More »

Medicare Winners Under New Healthcare Plans (MRK, PFE, AET, CI, CVH, HUM, UNH, WLP)

Everyone is trying to figure out who the winners and losers are likely to be under a watered-down healthcare program under the Obama administration and with a Democratic Congress.  What is certain is that changes to the old way of healthcare are coming, yet the uncertainty is becoming just how far away from the existing model this will get.  Mike Tarsala contributed a a brief round of explanations for the way this will likely impact drug giants Merck & Co. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE).  There is also a solid take on how companies like Humana Inc (NYSE: HUM), Coventry Health Care Inc. (NYSE: CVH), Cigna corp. (NYSE: CI), United Health (NYSE: UNH), WellPoint Inc. (NYSE: WLP) and Aetna Inc (NYSE: AET) are likely to be viewed.

More details of this can be seen at BioHealthInvestor.com.

Media Digest 6/22/2009 Reuters, WSJ, NYTimes, FT, Bloomberg.

newspaperReuters:   Airlines are cutting back on first class seating.

Reuters:   Xstrata wants merger talks with mining rival Anglo American.

Reuters:   Employers are cutting 401 (K) plans.

Reuters:   Brand loyalty is being hurt by the recession.

Reuters:   The children of baby boomers may help the US housing market. Read More »

Media Digest 6/19/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   Investors are putting money into emerging markets except Eastern Europe.

Reuters:   Stanford will go to court for a $8 billion fraud allegation.

Reuters:   RIM’s (RIMM) outlook disappointed.

Reuters:   CEOs at bailed out companies used corporate jets for private trips.

Reuters:   Congress may not accept all of Obama’s financial reforms. Read More »

Cramer’s Obama Healthcare Winner: WellPoint (WLP, CI, UNH, AET)

Cramer ImageJim Cramer came out with a healthcare maintenance  stock tonight on CNBC’s MAD MONEY which he thinks will survive and perhaps thrive under the Obama healthcare plan.  His pick in the healthcare maintenance sector is WellPoint Inc. (NYSE: WLP).  Cramer said he has not been in support of Cigna (NYSE: CI), UnitedHealth (NYSE:  UNH) and Aetna (NYSE: AET).  He also said he won’t be going there.

Read More »

Media Digest 6/16/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   The US outlined new financial market reforms.

Reuters:   Obama lobbied MDs on his new healthcare package.

Reuters:   Russia hosted the first BRIC summit.

Reuters:   B of A’s (BAC) BlackRock (BLK) stake is more appealing.

Reuters:   Samsung and Nokia (NOK) are pushing into smartphones. (MOT)(AAPL)(RIMM). Read More »

Media Digest 6/12/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:  Baclays (BCS) sold BCI to Blackrock (BLK) for $13.3 billion

Reuters:   WHO declared a flu epidemic

Reuters:   Congress bash Fed, Treasury, and B of A (BAC) on Merrill

Reuters:   US is near tighter control of tobacco by FDA.

Reuters:   New research shows mortgage delinquencies have bottomed

Reuters:   World Bank sees a steeper global economy contraction. Read More »

Analyst Projecting 50% Upside in Dendreon (DNDN)

Money Stack ImageDendreon Corporation (NASDAQ: DNDN) was started with a Buy rating and a $36.00 target at Deutsche Bank.  The call’s positive expectations are mixed near-term, but the assumption is that Provenge will become a blockbuster product in the fight against metastatic Prostate cancer. After looking through all the notes, it appears that this may be the second highest price target from all of the analysts out there.

Read More »

ASCO Winner: Biovest May Be The Next Dendreon (BVTI, ABPIQ, DNDN)

Money Stack ImageOne of the largest percentage gainers with data released at the American Society of Clinical Oncology was none other than an OTC micro-cap company called Biovest International, Inc. (OTC: BVTI).  Technically, this is a majority owned subsidiary company of Accentia Biopharmaceuticals, Inc. (OTC: ABPIQ).  The company has nothing to do with Dendreon Corp. (NASDAQ: DNDN) in the business, but the targets of the potential products use the body’s own immune system to fight tumors strike a similar interest.  And this weekend’s data released was far better than most were expecting from a company of this size.

We also covered this one in our weekly “10 Stocks under $10″ Newsletter as one with a big win under its belt.  The percentages of success were that large.  As noted:
Read More »

Media Digest 6/1/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   GM (GM) will file for Chapter 11 today.

Reuters:   Geithner told China its dollar assets are safe.

Reuters:   A judge approved the sale of most of Chrysler’s assets to a group led by Fiat.

Reuters:   German cut a deal to save Opel.

Reuters:   Private equity firm KKR lost $1.8 billion last year.

Reuters:   Elan is in talks to sell a stake to Bristol-Myers (BMY).

Reuters:   China’s economy is stabilizing and exports moved up slightly.

Reuters:   The Fed is puzzled by the steepening of the yield curve.

WSJ:   Ford (F) will increase production next quarter in an attempt to take business from its rivals.

WSJ:   “Lawmakers are pressing the Treasury Department to close a loophole to protect Social Security and disability benefits deposited in bank accounts from creditors.”

WSJ:   Emulux is expanding its push to prevent a takeover by Broadcom (BRCM).

WSJ:   Merck (MRK) and AstraZeneca are testing a new experimental cancer drug.

WSJ:   Geithner urges China to open its economy.

WSJ:   Emerging nations are increasing demand for key resources.

WSJ:   The Fed’s attempt to keep mortgage rates low is not working well.

WSJ:   The IMF expects jobs to trail GDP growth.

WSJ:   The demand for oil is staying low.

WSJ:   Weak demand for electricity could help consumers this summer.

WSJ:   Foreclosures are having a mixed impact on sales.

WSJ:   Temasek Holdings may sell its holding in Chartered Semiconductor.

WSJ:   Losses at homebuilders are expected to narrow.

WSJ:   International markets are at the center of the new stock rally.

WSJ:   The ISM data may not show a sharp recovery in the economy.

WSJ:   Improving results at banks are sending them on hiring sprees.

WSJ:   Commercial real estate will be a drawn-out problem for banks.

WSJ:   Retailers are felling the impact for foreclosures.

NYT:   The Big Three are no longer in a position to help bring the economy out of a recession.

NYT:   The battle for trading derivatives is at the heart of how much regulation of the banks is too much.

NYT:   Google (GOOG) will take on Amazon (AMZN) in the e-book business.

FT:   Microsoft (MSFT) and Sony (SNE) are taking aim at the market share of the Nintendo Wii.

FT:   A new reports says that the rebound in stocks cannot be sustained.

FT:   The US energy markets are bracing for hurricane season.

Bloomberg:   Goldman Sachs (GS) says commodity demand will produce a 19% return this year.

Douglas A. McIntyre

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend.   This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies:  Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Media Digest 5/27/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   GM (GM) is close to filing Chapter 11.

Reuters:   A poll of economists says the US recession will end soon followed by modest growth.

Retuers:   The mood of US consumers rose despite falling home prices.

Reuters:   Microsoft (MSFT) will launch a new Zune player later this year.

Reuters:   China tries to make Macau a better bet for casinos than Las Vegas. Read More »

Media Digest 5/20/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   The Treasury is keeping banks guessing about when they can repay TARP funds.

Reuters:   Bank of America (BAC) has raised more than $13 billion in share sales.

Reuters:   Hewlett-Packard’s (HPQ) financial outlook disappointed the market.

Reuters:   Terminated Chrysler dealers will challenge the sale of the company’s assets.

Reuters:   Obama is considering an agency to protect consumer’s financial interests.

Reuters:   Microsoft (MSFT) may unveil a new search engine.

Reuters:   Facebook’s CEO said an IPO is several years away. Read More »

Media Digest 5/19/2008 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   Twitter will release business tools in an attempt to make money.

Reuters:   A GM (GM) bankruptcy is seen as nearly inevitable.

Reuters:   American Express (AXP) will cut 4,000 jobs.

Reuters:   Obama will unveil aggressive car fuel standards.

Reuters:   Madoff trustee sues Fairfield Group for $3.5 billion

Reuters:   Mail blue collar workers are losing ground in employment and compensation. Read More »